MADRIGAL PHARMACEUTICALS, INC.
About MADRIGAL PHARMACEUTICALS, INC.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $958.4M
- Net income
- -$288.3M
- Total assets
- $1.3B
- Market cap
- $11.2B
- Operating margin
- -31.3%
- Net margin
- -30.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $958.4M
- Operating expenses
- $1.3B
- Operating income
- -$300.1M
- Income tax
- $0
- Net income
- -$288.3M
- EPS (basic)
- $-12.85
- EPS (diluted)
- $-12.85
Balance sheet
- Total assets
- $1.3B
- Current assets
- $1.2B
- Total liabilities
- $656.9M
- Current liabilities
- $310.3M
- Shareholders’ equity
- $602.7M
Cash flow
- Operating cash flow
- -$189.6M
- Investing cash flow
- $32.3M
- Financing cash flow
- $256.0M
- Net cash flow
- $98.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $11.2B
- EPS (diluted)
- $-12.85
- Shares outstanding
- 24.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 6, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $288.3M in FY2025.
- Trading 22% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MADRIGAL PHARMACEUTICALS, INC..
Write a review
News about MADRIGAL PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
